Altamira Therapeutics Company Description
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia.
The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues.
Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens.
The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021.
The company was founded in 2003 and is based in Hamilton, Bermuda.
| Country | Bermuda |
| Founded | 2003 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 10 |
| CEO | Thomas Meyer |
Contact Details
Address: Clarendon House Hamilton, HM 11 Bermuda | |
| Phone | 441 295 5950 |
| Website | altamiratherapeutics.com |
Stock Details
| Ticker Symbol | CYTOF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thomas Meyer | Chief Executive Officer |
| Marcel Gremaud | Chief Financial Officer |
| Covadonga Paneda | Chief Operating Officer |